Literature DB >> 1970536

The effect of xamoterol in failing human myocardium.

R H Schwinger1, M Böhm, E Erdmann.   

Abstract

As the dual pharmacological action of partial beta 1-adrenoceptor agonists should improve left ventricular function while also protecting the myocardium against excessive sympathetic stimulation they may be useful in the treatment of heart failure. Therefore, we studied the pharmacological effects of xamoterol (Corwin, ICI 118, 587), a compound with mixed agonist and antagonistic properties at cardiac beta-adrenoceptors in electrically driven human papillary muscle strips from failing human hearts. Specimens were obtained from patients with different grades of myocardial failure who underwent mitral valve replacement (NYHA II-III) or heart transplantation (NYHA IV). Xamoterol (0.0001-100 mumol l-1) produced only negative inotropic effects, as measured by changes in isometric force of contraction in diseased human papillary muscle strips. However, isoprenaline (0.0001-10 mumol l-1) and ouabain (0.01-0.3 mumol l-1) enhanced force of contraction in the same hearts. Prestimulation with noradrenaline (3 mumol l-1) augmented the negative inotropic effect of xamoterol. It is concluded that xamoterol exerts primarily beta-adrenoceptor antagonistic activity in the failing human myocardium.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970536     DOI: 10.1093/oxfordjournals.eurheartj.a059705

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  2 in total

1.  Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium.

Authors:  K Brixius; A Bundkirchen; B Bölck; U Mehlhorn; R H Schwinger
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

2.  The preferential beta3-adrenoceptor agonist BRL 37344 increases force via beta1-/beta2-adrenoceptors and induces endothelial nitric oxide synthase via beta3-adrenoceptors in human atrial myocardium.

Authors:  C Pott; K Brixius; A Bundkirchen; B Bölck; W Bloch; D Steinritz; U Mehlhorn; R H G Schwinger
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.